1. Home
  2. SLRC vs RLMD Comparison

SLRC vs RLMD Comparison

Compare SLRC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SLR Investment Corp.

SLRC

SLR Investment Corp.

HOLD

Current Price

$13.34

Market Cap

803.0M

Sector

Finance

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.85

Market Cap

752.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLRC
RLMD
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
803.0M
752.1M
IPO Year
2007
2012

Fundamental Metrics

Financial Performance
Metric
SLRC
RLMD
Price
$13.34
$6.85
Analyst Decision
Hold
Strong Buy
Analyst Count
7
5
Target Price
$15.14
$12.40
AVG Volume (30 Days)
558.8K
869.6K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
10.49%
N/A
EPS Growth
N/A
45.28
EPS
0.31
N/A
Revenue
N/A
$13,070.00
Revenue This Year
$1.09
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$42.05
N/A
Revenue Growth
N/A
154.83
52 Week Low
$12.83
$0.52
52 Week High
$17.20
$8.00

Technical Indicators

Market Signals
Indicator
SLRC
RLMD
Relative Strength Index (RSI) 41.25 45.89
Support Level $12.83 $6.81
Resistance Level $15.65 $7.46
Average True Range (ATR) 0.24 0.42
MACD 0.04 -0.04
Stochastic Oscillator 88.03 50.17

Price Performance

Historical Comparison
SLRC
RLMD

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: